New antiangiogenic agents for renal cell carcinoma: bevacizumab.
Bukowski
Ronald M
RM
Experimental Therapeutics Program, Cleveland Clinic Cancer Center, S33, 9500 Euclid Avenue, Cleveland, OH 441195, USA.